Considering that many cancers simultaneously express CD166 and CD318, which bind to different epitopes of CD6, the functional consequences of CD6-mediated interactions between cancer cells and lymphocytes may be a blend of distinct signals from each ligand. Here, CDCP1 is linked to cancer.